The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Structures of oncogenic, suppressor and rescued p53 core-domain variants: mechanisms of mutant p53 rescue
Abstract
To gain insights into the mechanisms by which certain second-site suppressor mutations rescue the function of a significant number of cancer mutations of the tumor suppressor protein p53, X-ray crystallographic structures of four p53 core-domain variants were determined. These include an oncogenic mutant, V157F, two single-site suppressor mutants, N235K and N239Y, and the rescued cancer mutant V157F/N235K/N239Y. The V157F mutation substitutes a smaller hydrophobic valine with a larger hydrophobic phenylalanine within strand S4 of the hydrophobic core. The structure of this cancer mutant shows no gross structural changes in the overall fold of the p53 core domain, only minor rearrangements of side chains within the hydrophobic core of the protein. Based on biochemical analysis, these small local perturbations induce instability in the protein, increasing the free energy by 3.6 kcal mol−1(15.1 kJ mol−1). Further biochemical evidence shows that each suppressor mutation, N235K or N239Y, acts individually to restore thermodynamic stability to V157F and that both together are more effective than either alone. All rescued mutants were found to have wild-type DNA-binding activity when assessed at a permissive temperature, thus pointing to thermodynamic stability as the critical underlying variable. Interestingly, thermodynamic analysis shows that while N239Y demonstrates stabilization of the wild-type p53 core domain, N235K does not. These observations suggest distinct structural mechanisms of rescue. A new salt bridge between Lys235 and Glu198, found in both the N235K and rescued cancer mutant structures, suggests a rescue mechanism that relies on stabilizing the β-sandwich scaffold. On the other hand, the substitution N239Y creates an advantageous hydrophobic contact between the aromatic ring of this tyrosine and the adjacent Leu137. Surprisingly, the rescued cancer mutant shows much larger structural deviations than the cancer mutant alone when compared with wild-type p53. These suppressor mutations appear to rescue p53 function by creating novel intradomain interactions that stabilize the core domain, allowing compensation for the destabilizing V157F mutation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Crystal structures show that the second-site suppressor mutations usually cause only small local structural changes, whereas do not alter the overall structure of the p53 protein.534,536,545,546”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [545]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,551 · cited 4×
“The core domain consists of a -sandwich scaffold which defines the DNA-binding surface (Cho et al., 1994).”
BackgroundInfluentialPetitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598 · cited 2×
“Statistical analysis shows that about half of all human tumors carry mutant p53 alleles, about 70% of which are single-site missense mutations located in the core domain (IARC TP53 Database, version R16; http:// p53.iarc.fr; Vousden & Lu, 2002; Petitjean et al., 2007).”
BackgroundRestoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067 · cited 1×
“Over the past decade, a variety of cell-based screening techniques have led to the discovery of several small molecules which appear to rescue the function of mutant p53 (Foster et al., 1999; Bykov et al., 2002; Yu et al., 2012).”
BackgroundUnraveling hot spots in binding interfaces: progress and challenges
DeLano, W. L. (2002) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(02)00283-x · Cited by 767
Lehmann, S., Bykov, V. J. N., Ali, D., Andrén, O., Cherif, H., Tidefelt, U., Uggla, B., Yachnin, J., Juliusson, G., Moshfegh, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7783 · Cited by 406 · cited 2×
“One of these small molecules, APR246 (PRIMA-1MET), is currently in Phase I/II clinical trials (Lehmann et al., 2012).”
BackgroundHow p53 binds DNA as a tetramer
McLure, K. G., & Lee, P. W. K. (1998) · The EMBO Journal · doi:10.1093/emboj/17.12.3342 · Cited by 260
Research works printed but not linked: 43
- Adams, 2010, Acta Cryst. D, 66, 213, 10.1107/S0907444909052925 · DOI · Paper page
- Afonine, 2012, Acta Cryst. D, 68, 352, 10.1107/S0907444912001308 · DOI · Paper page
- Aramayo, 2011, Nucleic Acids Res., 39, 8960, 10.1093/nar/gkr386 · DOI · Paper page
- Baroni, 2004, Proc. Natl Acad. Sci. USA, 101, 4930, 10.1073/pnas.0401162101 · DOI
- Brachmann, 2004, Cell Cycle, 3, 1030, 10.4161/cc.3.8.1076 · doi:10.4161/cc.3.8.1076
- Brachmann, 1998, EMBO J., 17, 1847, 10.1093/emboj/17.7.1847 · DOI · Paper page
- Brünger, 1998, Acta Cryst. D, 54, 905, 10.1107/S0907444998003254 · DOI · Paper page
- Bullock, 2001, Nature Rev. Cancer, 1, 68, 10.1038/35094077 · DOI · Paper page
- Bullock, 1997, Proc. Natl Acad. Sci. USA, 94, 14338, 10.1073/pnas.94.26.14338 · DOI · Paper page
- Bullock, 2000, Oncogene, 19, 1245, 10.1038/sj.onc.1203434 · DOI · Paper page
- Chen, 2010, Acta Cryst. D, 66, 12, 10.1107/S0907444909042073 · DOI · Paper page
- Danziger, 2007, Bioinformatics, 23, i104, 10.1093/bioinformatics/btm166 · DOI
- Emsley, 2004, Acta Cryst. D, 60, 2126, 10.1107/S0907444904019158 · DOI · Paper page
- Evans, 2006, Acta Cryst. D, 62, 72, 10.1107/S0907444905036693 · DOI · Paper page
- Foster, 1999, Science, 286, 2507, 10.1126/science.286.5449.2507 · DOI · Paper page
- Joerger, 2004, J. Biol. Chem., 279, 1291, 10.1074/jbc.M309732200 · DOI · Paper page
- Joerger, 2006, Proc. Natl Acad. Sci. USA, 103, 15056, 10.1073/pnas.0607286103 · DOI · Paper page
- Joerger, 2005, J. Biol. Chem., 280, 16030, 10.1074/jbc.M500179200 · DOI · Paper page
- Joerger, 2008, Annu. Rev. Biochem., 77, 557, 10.1146/annurev.biochem.77.060806.091238 · DOI · Paper page
- Jones, 1991, Acta Cryst. A, 47, 110, 10.1107/S0108767390010224 · DOI · Paper page
- Krissinel, 2004, Acta Cryst. D, 60, 2256, 10.1107/S0907444904026460 · DOI · Paper page
- Kruse, 2009, Cell, 137, 609, 10.1016/j.cell.2009.04.050 · DOI · Paper page
- Laskowski, 1996, J. Biomol. NMR, 8, 477, 10.1007/BF00228148 · DOI · Paper page
- Melero, 2011, Proc. Natl Acad. Sci. USA, 108, 557, 10.1073/pnas.1015520107 · DOI · Paper page
- Nikolova, 1998, Proc. Natl Acad. Sci. USA, 95, 14675, 10.1073/pnas.95.25.14675 · DOI · Paper page
- Nikolova, 2000, EMBO J., 19, 370, 10.1093/emboj/19.3.370 · DOI · Paper page
- Pace, 1986, Methods Enzymol., 131, 266, 10.1016/0076-6879(86)31045-0 · DOI · Paper page
- Pflugrath, 1999, Acta Cryst. D, 55, 1718, 10.1107/S090744499900935X · DOI · Paper page
- Riley, 2008, Nature Rev. Mol. Cell Biol., 9, 402, 10.1038/nrm2395 · DOI · Paper page
- Rippin, 2002, J. Mol. Biol., 319, 351, 10.1016/S0022-2836(02)00326-1 · DOI · Paper page
- Römer, 2006, Angew. Chem. Int. Ed. Engl., 45, 6440, 10.1002/anie.200600611 · DOI · Paper page
- Senear, 1991, J. Biol. Chem., 266, 13661, 10.1016/S0021-9258(18)92751-1 · doi:10.1016/s0021-9258(18)92751-1
- Storoni, 2004, Acta Cryst. D, 60, 432, 10.1107/S0907444903028956 · DOI · Paper page
- Suad, 2009, J. Mol. Biol., 385, 249, 10.1016/j.jmb.2008.10.063 · DOI · Paper page
- Tretyachenko-Ladokhina, 2006, J. Mol. Biol., 362, 271, 10.1016/j.jmb.2006.06.085 · DOI
- Vogelstein, 2000, Nature (London), 408, 307, 10.1038/35042675 · DOI · Paper page
- Vousden, 2002, Nature Rev. Cancer, 2, 594, 10.1038/nrc864 · DOI · Paper page
- Wang, 2003, Cancer Biol. Ther., 2, S55
- Wang, 2007, Acta Cryst. D, 63, 276, 10.1107/S0907444906048499 · DOI
- Wassman, 2013, Nature Commun., 4, 1407, 10.1038/ncomms2361 · DOI · Paper page
- Weinberg, 2004, J. Mol. Biol., 341, 1145, 10.1016/j.jmb.2004.06.071 · DOI · Paper page
- Wieczorek, 1996, Nature Med., 2, 1143, 10.1038/nm1096-1143 · DOI
- Yu, 2012, Cancer Cell, 21, 614, 10.1016/j.ccr.2012.03.042 · DOI · Paper page
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches
Joerger, A. C., & Fersht, A. R. (2016) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060815-014710 · Cited by 661
Metadata
- Authors
- Wallentine, B. D., Wang, Y., Tretyachenko-Ladokhina, V., Tan, M., Senear, D. F., & Luecke, H.
- Venue
- Acta Crystallographica Section D Biological Crystallography
- Published
- 2013-09-20
- Volume
- 69
- Issue
- 10
- Pages
- 2146-2156
- ISSN
- 0907-4449
- Cited by
- 15
- References
- 6
- Licence
- journals.iucr.org/services/copyrightpolicy.html (vor)
- journals.iucr.org/services/copyrightpolicy.html#TDM (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.